Insight Molecular Diagnostics Inc. Dividends
The next dividend date for Insight Molecular Diagnostics Inc. has not yet been scheduled.
What is a Dividend Date
When we talk about a dividend date, we’re referring specifically to the ex-dividend date.
This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.
The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.
Most brokerages will automatically credit the dividend to your account once it’s issued.
Historical Dividends for Insight Molecular Diagnostics Inc. (IMDX)
More About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Owning Insight Molecular Diagnostics Inc. Stock on the Dividend Date
If you own Insight Molecular Diagnostics Inc. stock on the ex-dividend date, then you earn the associated dividend.
Theoretically, the price of Insight Molecular Diagnostics Inc. stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of Insight Molecular Diagnostics Inc. stock).
Therefore, it is typically not expected that there is any incremental profit to be gained from buying Insight Molecular Diagnostics Inc. stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the Insight Molecular Diagnostics Inc. dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.
Learning More Insight Molecular Diagnostics Inc. Dividends
You can contact us any time if you would like to ask questions about Insight Molecular Diagnostics Inc. dividends or anything else related to the stock market.